Haemonetics Co. (NYSE:HAE) Shares Purchased by Hood River Capital Management LLC

Hood River Capital Management LLC lifted its holdings in Haemonetics Co. (NYSE:HAE - Free Report) by 6.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 214,290 shares of the medical instruments supplier's stock after acquiring an additional 13,710 shares during the period. Hood River Capital Management LLC owned approximately 0.43% of Haemonetics worth $16,732,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Nordea Investment Management AB raised its position in shares of Haemonetics by 5.5% in the 4th quarter. Nordea Investment Management AB now owns 104,175 shares of the medical instruments supplier's stock valued at $8,152,000 after purchasing an additional 5,385 shares in the last quarter. Janney Montgomery Scott LLC bought a new position in shares of Haemonetics during the fourth quarter worth about $402,000. KBC Group NV grew its stake in Haemonetics by 54.6% in the fourth quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier's stock worth $157,000 after purchasing an additional 712 shares in the last quarter. Pacer Advisors Inc. raised its stake in Haemonetics by 36.1% during the fourth quarter. Pacer Advisors Inc. now owns 10,104 shares of the medical instruments supplier's stock valued at $789,000 after buying an additional 2,680 shares in the last quarter. Finally, Boston Trust Walden Corp lifted its stake in Haemonetics by 13.1% during the fourth quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier's stock worth $71,500,000 after purchasing an additional 106,114 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on HAE shares. Raymond James reaffirmed a "strong-buy" rating and issued a $115.00 target price (down from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. Needham & Company LLC cut their price objective on shares of Haemonetics from $108.00 to $104.00 and set a "buy" rating on the stock in a research report on Tuesday, March 18th. StockNews.com cut shares of Haemonetics from a "buy" rating to a "hold" rating in a research report on Saturday, February 15th. Bank of America lowered Haemonetics from a "neutral" rating to an "underperform" rating and decreased their price objective for the stock from $95.00 to $68.00 in a report on Friday, February 7th. Finally, Barrington Research decreased their price objective on shares of Haemonetics from $108.00 to $95.00 and set an "outperform" rating for the company in a report on Friday, February 7th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Haemonetics has an average rating of "Moderate Buy" and a consensus price target of $101.22.

Haemonetics Stock Performance

Haemonetics stock opened at $59.22 on Wednesday. The firm's 50 day simple moving average is $62.91 and its 200-day simple moving average is $72.44. Haemonetics Co. has a fifty-two week low of $55.30 and a fifty-two week high of $97.97. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55. The company has a market cap of $2.98 billion, a P/E ratio of 23.31, a price-to-earnings-growth ratio of 1.11 and a beta of 0.41.

Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. As a group, equities research analysts predict that Haemonetics Co. will post 4.55 EPS for the current year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.